Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Short SellingSee which listed companies have disclosed short interest
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Log in to your Inderes Free account to see all free content on this page.
Create account

Atria

15.86 EUR-0.13 %10.11. klo 11.15
5,730 following

ATRAV

NASDAQ Helsinki

Food & Beverage

Consumer Goods & Services

Overview
Financials & Estimates
Ownership
Dividend
Short Selling
Investor views
Compare
-0.13 %
+0.63 %
+1.15 %
+9.08 %
+3.66 %
+12.88 %
+51.05 %
+38.39 %
+84.90 %

Atria is a food group. The group includes several players, the better known of which include Sibylla, Lithells and Ridderheims. The subsidiaries' operations include the production of liver pâté, meat and chicken products, and various finished products. The operations are conducted on a global level, mainly concentrated in the Nordic countries, the Baltics and Russia. The company was founded in 1903 and has its headquarters in Seinäjoki.

Read more
Market cap
449.91M EUR
Turnover
12.69K EUR
P/E (adj.) (26e)
EV/EBIT (adj.) (26e)
P/B (26e)
EV/S (26e)
Dividend yield-% (26e)
Coverage
Recommendation
Accumulate
Target price
Updated
22.10.2026
Disclaimer
Revenue and EBIT-%
EPS and dividend
Financial calendar
Risk
Business risk
Valuation risk
Low
High
All
Research
Webcasts
Press releases
3rd party
ShowingAll content types

Forum discussions
Here is a company report on Atria regarding Q3 from Pauli and Anton The Q3 result was in line with our expectations, as strong earnings growth in Sweden compensated for the export losses caused by the swine fever. Sweden’s strong commercial momentum and strategic investments will...
10/22/2026, 6:20 PM
by Sijoittaja-alokas
4
@henrielo has written about Atria. Atria’s debt level is under control. Net debt to adjusted EBITDA stands at 2.0, which is a good level. This year and next year will be heavy investment years. The largest investment project, totaling around 110 million euros, is the new prepared...
10/23/2026, 1:34 PM
by Sijoittaja-alokas
3
Here are Pauli’s and Antoni’s comments on the Q3 results Atria reported its Q3 results today, which were in line with our expectations. Revenue grew by 4%, and adjusted operating profit was stable at EUR 25.3 million. African swine fever slowed earnings growth as anticipated, but...
10/22/2026, 6:50 AM
by Sijoittaja-alokas
3
Previously HKScan was the one whose name appeared in these animal cruelty scandals, but they know how to do it on Atria’s contract farms as well: Helsingin Sanomat – 1 Sep 26 Tehotuotanto | Atria poisti sikoja saastaisissa olosuhteissa pitäneen tilan... Atrian sivuilla mainostettiin...
9/1/2026, 12:42 PM
3
Here are Pauli’s comments on Atria’s release regarding the impacts of swine fever. Inderes – 7 Aug 26 Atria: Sikaruton vaikutukset merkittävät, tulos kasvaa silti - Inderes Yhtiö piti ennallaan nousujohteisen tulosohjeistuksen merkittävästä haitasta huolimatta.
8/7/2026, 8:10 AM
by Sijoittaja-alokas
3
Swine fever has arrived in Finland. - Ruohola estimates that the biggest problems are related to the Chinese and Japanese markets. “It looks like the export ban to China and Japan could last for up to three years. This is a big blow to Finland’s pig farming industry and also to us...
7/30/2026, 4:44 PM
by Sheikki
3
Here is a new company report on Atria from Pauli following the Q2 results Q2 strengthened our confidence in the company’s earnings growth through both the actual figures and the progress made in its strategy. The effects of cost inflation will intensify in H2, but we believe the ...
7/22/2026, 10:21 PM
by Sijoittaja-alokas
3
Read more on our forum
Pauli Lohi
Pauli Lohi

Analyst

Revenue and EBIT-%

Revenue B

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
12.2.
2027

Annual report '26

22.4.
2027

General meeting '27

22.4.
2027

Interim report Q1'27

Atria Oyj, CMD
Webcast25.11.2026 klo 10.00

Atria Oyj, CMD

Atria
Third party research23.10.2026 klo 08.39

Atria: Sweden is gaining traction - Nordea

Atria's Q3 results were in line with LSEG Data & Analytics consensus expectations. The African Swine Fever outbreak in Finland had around a EUR 2m negative impact in Q3, while Atria Sweden improved its profitability significantly. The company is clearly...

Atria
Third party research22.10.2026 klo 10.09

Atria: Q3 in line with expectations with a strong Sweden - Nordea

Atria reported Q3 adjusted EBIT of EUR 25.3m, 1% above LSEG Data & Analytics consensus. Q3 net sales of EUR 475m were up 4% y/y and came in line with consensus. Sweden and Denmark & Estonia EBIT were ahead of our expectation while Finland missed slightly...

Atria

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and deep analyses
Premium tools: model portfolio, screener, insider transactions
Premium columns: Guest column, expert insights
Inderes MCP - Inderes data directly into your AI tools
Create account
Regulatory press release22.10.2026 klo 08.00

Interim Report of Atria Plc, 1 January - 30 September 2026

Atria
Third party research16.10.2026 klo 08.22

Atria: We expect strong underlying performance in Q3 - Nordea

Ahead of Atria's Q3 results, we trim 2026E-28E adjusted EBIT by 4-6% owing to the ASF outbreak in Finland and expected raw material inflation. We expect solid underlying performance in Finland, while the company expects a EUR 4-5m negative impact from...

Atria
Regulatory press release17.09.2026 klo 12.30

Atria Oyj: Atria Plc's Board of Directors resolved on a directed share issue without consideration to the company itself

Atria
Analyst Comment02.09.2026 klo 09.45
by Pauli Lohi

Atria and HKFoods: Export restrictions caused by African swine fever are plaguing otherwise strongly performing companies

It is impossible to estimate the duration of the export restrictions caused by African swine fever.

AtriaHKFoods
Third party research07.08.2026 klo 09.34

Atria: Negative impact from ASF above our earlier thinking - Nordea

Atria expects EUR -7m annualised EBIT impact to its Finnish export business from ASF outbreak in Finland. The company assumes that exports to China and Japan will be discontinued while pork sales to South Korea will continue. Atria expects EUR 4-5m negative...

Atria
Regulatory press release07.08.2026 klo 08.30

Atria Oyj: Estimated impact of the ASF findings in Finland on Atria's result

Atria
Third party research31.07.2026 klo 09.29

Asia: First ASF case in Finland will impact export opportunities - Nordea

Based on its preliminary results, Finnish Food Authority has found African Swine Fever (ASF) in Finland from a wild boar. This is the first ever case in Finland and will likely impact export opportunities to, especially Asia. For Atria, ASF could pause...

Atria
Analyst Comment31.07.2026 klo 11.47
by Pauli Lohi

Atria and HKFoods: Discovery of swine fever weakens export revenues

The interruption of exports could weaken earnings by an estimated 3-5%.

HKFoodsAtria
Third party research23.07.2026 klo 08.08

Atria: Strong start to the grilling season - Nordea

Atria's Q2 adjusted EBIT of EUR 20.7m was 15% above LSEG Data & Analytics consensus and sales were 1% above. The company noted a strong start to the grilling season, while cost inflation started to intensify towards the end of the quarter. However, we...

Atria
Third party research22.07.2026 klo 09.26

Atria: Strong Q2 driven by Finland - Nordea

Atria reported Q2 adjusted EBIT of EUR 20.7m, 15% above LSEG Data & Analytics consensus. Q2 net sales of EUR 481m were up 5% y/y and came 1% above consensus. Sweden and Denmark & Estonia EBIT were slightly ahead of our expectation while Finland beat ...

Atria
Regulatory press release22.07.2026 klo 08.00

Half-year financial report of Atria Plc, 1 January - 30 June 2026

Atria
Third party research15.07.2026 klo 11.55

Atria: Q2 2026 preview - Nordea

Ahead of Atria's Q2 report, we make only minor estimate revisions and derive a DCF- and multiples-based fair value range of EUR 18.3-22.3 (18.1-22.1). We believe the Finnish grocery market has continued on a slightly positive trajectory, while the company...

Atria
Regulatory press release24.06.2026 klo 14.45

Atria Oyj: Composition of Atria Plc's Nomination Board

Atria
Regulatory press release28.05.2026 klo 13.30

Atria Oyj: Atria's financial reporting in 2027

Atria
Third party research24.04.2026 klo 08.26

Atria: Strong top-line momentum continues - Nordea

Atria's Q1 was solid with adjusted EBIT beating LSEG Data & Analytics consensus by 6%. Higher subsidies supported the development in Estonia, while an avian influenza-driven shortage of poultry impacted sales and earnings negatively in Sweden. Ahead ...

Atria
Regulatory press release23.04.2026 klo 16.00

Atria Oyj: Appointments to the Supervisory Board, Board of Directors and Nomination and Remuneration Committee of Atria Plc

Atria
Regulatory press release23.04.2026 klo 14.45

Atria Oyj: Decisions of Atria Plc's Annual General Meeting

Atria